Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 5Phase NA 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 3Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5

Conditions

Ovarian Neoplasms 805Uterine Cervical Neoplasms 412Fallopian Tube Neoplasms 289Endometrial Neoplasms 287Carcinoma, Ovarian Epithelial 252Neoplasms 95Recurrence 83Breast Neoplasms 83Peritoneal Neoplasms 66Uterine Neoplasms 55Colorectal Neoplasms 55Uterine Cervical Dysplasia 50Sarcoma 49Vulvar Neoplasms 47Carcinoma, Non-Small-Cell Lung 45Neoplasm Metastasis 44Stomach Neoplasms 42Pancreatic Neoplasms 36Melanoma 34Testicular Neoplasms 32Lung Neoplasms 32Prostatic Neoplasms 29Vaginal Neoplasms 28Papillomavirus Infections 25Carcinoma 25Head and Neck Neoplasms 23Esophageal Neoplasms 23Carcinoma, Renal Cell 23Small Cell Lung Carcinoma 22Urinary Bladder Neoplasms 21

Interventions

Paclitaxel 2liposomal doxorubicin 1Tocotrienols 1Platinum Compounds 1EP-100 membrane-disrupting peptide 1Carboplatin 1Bevacizumab 1AC 7700 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Ovarian Cancer Recurrent × Gynecologic × Clear all
NCT07295132 2025-12-19

RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)

Asan Medical Center

Phase 2 Not yet recruiting
160 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT06014528 2025-04-30

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

InxMed (Shanghai) Co., Ltd.

Phase 2 Recruiting
168 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT04175470 2025-01-03

Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

Vejle Hospital

Phase 2 Completed
20 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT01332656 2015-12-21

OPSALIN

Sanofi

Phase 2 Completed
154 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT01485848 2014-06-10

ESP2011-002

Esperance Pharmaceuticals Inc

Phase 2 Completed
49 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡